08/30/2024
8:00 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/30/2024
7:56 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/28/2024
3:39 PM | Ligand Pharmaceuticals (Subject)
Reardon Andrew (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/26/2024
7:15 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/22/2024
5:05 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/13/2024
4:21 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/09/2024
4:52 PM | Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
|
08/09/2024
4:16 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/07/2024
3:30 PM | Ligand Pharmaceuticals (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
07/17/2024
4:10 PM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/10/2024
3:02 PM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/08/2024
6:38 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
07/02/2024
6:44 PM | Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/02/2024
6:45 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/02/2024
6:45 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/02/2024
6:45 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/27/2024
8:10 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/25/2024
6:45 PM | Ligand Pharmaceuticals (Issuer)
Sabba Stephen L (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
8:25 PM | Aryeh Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
8:26 PM | Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
8:26 PM | Haas Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
8:26 PM | KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
8:27 PM | LAMATTINA JOHN L (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
8:27 PM | Ligand Pharmaceuticals (Issuer)
Zimmermann Martine (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
4:14 PM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/17/2024
6:59 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/17/2024
7:00 PM | Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/17/2024
4:45 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/16/2024
4:39 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/15/2024
6:34 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/15/2024
5:01 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/15/2024
1:45 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144/A | |
05/14/2024
6:42 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/13/2024
5:14 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/13/2024
4:32 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/09/2024
5:03 PM | Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/09/2024
5:06 PM | Ligand Pharmaceuticals (Subject)
Reardon Andrew (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/09/2024
3:11 PM | Ligand Pharmaceuticals (Filer)
| Form DEFA14A | |
05/07/2024
6:36 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/02/2024
5:07 PM | Aryeh Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/26/2024
5:35 PM | KOZARICH JOHN W (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
The death of Nvidia? (Ad) Today, I’m warning of another looming catastrophe.
Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out.
You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy...
There's also no escaping that The Big AI Die-Up is coming. So go here now to read my new report The Big AI Die-Up… while you still can. |
03/27/2024
4:47 PM | Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/07/2024
12:27 PM | Ligand Pharmaceuticals (Issuer)
Sabba Stephen L (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/06/2024
4:28 PM | Aryeh Jason (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/05/2024
5:12 PM | Ligand Pharmaceuticals (Subject)
Sabba Stephen L (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/29/2024
5:49 PM | Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/29/2024
5:50 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/29/2024
5:50 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/29/2024
5:50 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/29/2024
3:49 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144/A | |
02/29/2024
3:16 PM | Ligand Pharmaceuticals (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
02/28/2024
5:05 PM | Gray Nancy Ryan (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/28/2024
4:43 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/27/2024
6:24 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/16/2024
7:10 PM | Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/16/2024
7:10 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/16/2024
7:10 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/16/2024
7:10 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/14/2024
5:26 AM | Ligand Pharmaceuticals (Subject)
MACQUARIE GROUP LTD (Filed by)
| Form SC 13G | |
02/13/2024
2:39 PM | JANUS HENDERSON GROUP PLC (Filed by)
Ligand Pharmaceuticals (Subject)
| Form SC 13G/A | |
02/12/2024
6:42 PM | GOLDMAN SACHS GROUP INC (Filed by)
GOLDMAN SACHS GROUP INC (Filed by)
Ligand Pharmaceuticals (Subject)
| Form SC 13G | |
01/22/2024
1:03 PM | BlackRock Inc. (Filed by)
Ligand Pharmaceuticals (Subject)
| Form SC 13G/A | |
01/04/2024
3:07 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/04/2024
3:07 PM | Ligand Pharmaceuticals (Issuer)
Reardon Andrew (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/06/2023
2:27 PM | Korenberg Matthew E (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/06/2023
2:27 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
12/01/2023
7:25 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/18/2023
8:03 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/03/2023
3:36 PM | Espinoza Octavio (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/27/2023
7:38 AM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
09/26/2023
3:41 PM | Ligand Pharmaceuticals (Issuer)
Zimmermann Martine (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/25/2023
5:12 PM | Ligand Pharmaceuticals (Issuer)
Zimmermann Martine (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
09/25/2023
3:44 PM | Davis Todd C (Reporting)
Ligand Pharmaceuticals (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/18/2023
4:26 PM | Ligand Pharmaceuticals (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
